Scholars@Duke
Joshua Clair Snyder

Joshua Clair Snyder

Adjunct Professor in the Department of Surgery
Surgery, Surgical Sciences
203 Research Drive, MSRB1 475A, DUMC 2606, Durham, NC 27710
MSRBI Rm 475A, Durham, NC 27710

Scholarly Works - Other

FIGURE 2 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>Mutant GFP and luciferase induce immune responses comparable with wild-type (WT) proteins. <b>A,</b> WT male Balb/c mice were vaccinated with Ad encoding WT or mutant copies of GFP (ΔT64; <i>n</i> = 5/group) and ser ... Full text Cite

Figure S2 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>Validating mutant GFP and Luc activity in Adenovirus vaccines</p> ... Full text Cite

FIGURE 7 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>Summary of tumor behavior in differentially tolerant animal models. <b>A,</b> Xenoantigen-bearing tumor cells implanted orthotopically into immune-deficient mice typically grow and metastasize as expected and can be easily obse ... Full text Cite

FIGURE 6 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>NoGlow mice reveal unappreciated metastatic dynamics independent of the primary tumor. <b>A,</b> Tumor growth of triple transgenic (3 ×) B16-F10 cells (10<sup>5</sup>) after subcutaneous implantation into the flank ... Full text Cite

FIGURE 5 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>Tumor cells expressing GFP, rtTA, and Luciferase successfully engraft in NoGlow mice. <b>A,</b> Diagram of triple-transgenic (3 ×) E0771 cells. GFP and rtTA are constitutively expressed and Luc is induced with the addition of d ... Full text Cite

FIGURE 6 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>NoGlow mice reveal unappreciated metastatic dynamics independent of the primary tumor. <b>A,</b> Tumor growth of triple transgenic (3 ×) B16-F10 cells (10<sup>5</sup>) after subcutaneous implantation into the flank ... Full text Cite

Figure S4 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>Confirming triple-transgenic GFP rtTA-Luc construct in E0771 cells</p> ... Full text Cite

FIGURE 4 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>NoGlow mice reveal the impact of sex and tissue distribution on immune tolerance. <b>A,</b> Male WT (<i>n</i> = 3), CAG Luc-GFP (<i>n</i> = 3), and NoGlow+ (<i>n</i> = 6) or NoGlow− (<i&gt ... Full text Cite

Figure S1 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>Additional E0771 tumor growth in WT, GH, and CAG Luc-GFP mice; MMTV CAG HER2 Ad-HER2 vaccination T cell responses.</p> ... Full text Cite

FIGURE 7 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>Summary of tumor behavior in differentially tolerant animal models. <b>A,</b> Xenoantigen-bearing tumor cells implanted orthotopically into immune-deficient mice typically grow and metastasize as expected and can be easily obse ... Full text Cite

Data from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <div>Abstract<p>The ability to temporally regulate gene expression and track labeled cells makes animal models powerful biomedical tools. However, sudden expression of xenobiotic genes [e.g., GFP, luciferase (Luc), or rtTA3] can trigger ... Full text Cite

Data from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <div>Abstract<p>The ability to temporally regulate gene expression and track labeled cells makes animal models powerful biomedical tools. However, sudden expression of xenobiotic genes [e.g., GFP, luciferase (Luc), or rtTA3] can trigger ... Full text Cite

FIGURE 1 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>Tolerance to foreign antigens is animal model specific. <b>A</b> and <b>B,</b> Mice expressing GFP and Luc in the pituitary (GH; <i>n</i> = 5), full-body GFP, and Luc (CAG Luc-GFP; <i>n</i> = ... Full text Cite

FIGURE 3 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>NoGlow mice express eGFP and Luciferase without background fluorescence and bioluminescence. <b>A,</b> Diagram of the NoGlow construct. LoxP-flanked stop site prevents expression of the NoGlow construct in the absence of Cre re ... Full text Cite

FIGURE 4 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>NoGlow mice reveal the impact of sex and tissue distribution on immune tolerance. <b>A,</b> Male WT (<i>n</i> = 3), CAG Luc-GFP (<i>n</i> = 3), and NoGlow+ (<i>n</i> = 6) or NoGlow− (<i&gt ... Full text Cite

FIGURE 5 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>Tumor cells expressing GFP, rtTA, and Luciferase successfully engraft in NoGlow mice. <b>A,</b> Diagram of triple-transgenic (3 ×) E0771 cells. GFP and rtTA are constitutively expressed and Luc is induced with the addition of d ... Full text Cite

Figure S4 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>Confirming triple-transgenic GFP rtTA-Luc construct in E0771 cells</p> ... Full text Cite

FIGURE 3 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>NoGlow mice express eGFP and Luciferase without background fluorescence and bioluminescence. <b>A,</b> Diagram of the NoGlow construct. LoxP-flanked stop site prevents expression of the NoGlow construct in the absence of Cre re ... Full text Cite

FIGURE 1 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>Tolerance to foreign antigens is animal model specific. <b>A</b> and <b>B,</b> Mice expressing GFP and Luc in the pituitary (GH; <i>n</i> = 5), full-body GFP, and Luc (CAG Luc-GFP; <i>n</i> = ... Full text Cite

FIGURE 2 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>Mutant GFP and luciferase induce immune responses comparable with wild-type (WT) proteins. <b>A,</b> WT male Balb/c mice were vaccinated with Ad encoding WT or mutant copies of GFP (ΔT64; <i>n</i> = 5/group) and ser ... Full text Cite

Figure S2 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>Validating mutant GFP and Luc activity in Adenovirus vaccines</p> ... Full text Cite

Figure S1 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

Other · April 9, 2024 <p>Additional E0771 tumor growth in WT, GH, and CAG Luc-GFP mice; MMTV CAG HER2 Ad-HER2 vaccination T cell responses.</p> ... Full text Cite

Movie 1 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

Other · April 3, 2023 <p>p95HER2 labelled sidebuds. p95HER2 shown in magenta. Krt14 antibody staining shown in green.</p><p></p> ... Full text Cite

Movie 3 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

Other · April 3, 2023 <p>p95HER2 invasive carcinoma. p95HER2 shown in magenta. Krt14 antibody staining shown in green.</p> ... Full text Cite

Movie 4 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

Other · April 3, 2023 <p>p95HER2 microinvasive carcinoma. p95HER2 shown in magenta. Krt14 antibody staining shown in green.</p> ... Full text Cite

Movie 5 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

Other · April 3, 2023 <p>d16HER2 mammary intraepithelial neoplasm. d16HER2 shown in magenta. Krt14 antibody staining shown in green.</p> ... Full text Cite

Movie 2 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

Other · April 3, 2023 <p>d16HER2 labelled sidebuds. d16HER2 shown in yellow. Krt14 antibody staining shown in green.</p> ... Full text Cite

Movie 4 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

Other · April 3, 2023 <p>p95HER2 microinvasive carcinoma. p95HER2 shown in magenta. Krt14 antibody staining shown in green.</p> ... Full text Cite

Supplementary Tables 1-5 for scRNAseq marker genes from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

Other · April 3, 2023 <p>Supplementary Table 1: Cluster-specific markers from all cells (8,486 cells) Supplementary Table 2: Cluster-specific markers from all epithelial cells (3,843 cells) Supplementary Table 3: Cluster-specific markers from all immune cells (1,8 ... Full text Cite

Movie 5 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

Other · April 3, 2023 <p>d16HER2 mammary intraepithelial neoplasm. d16HER2 shown in magenta. Krt14 antibody staining shown in green.</p> ... Full text Cite

Movie 1 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

Other · April 3, 2023 <p>p95HER2 labelled sidebuds. p95HER2 shown in magenta. Krt14 antibody staining shown in green.</p><p></p> ... Full text Cite

Data from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

Other · April 3, 2023 <div>Abstract<p>HER2-positive breast cancers are among the most heterogeneous breast cancer subtypes. The early amplification of HER2 and its known oncogenic isoforms provide a plausible mechanism in which distinct programs of tumor het ... Full text Cite

Movie 3 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

Other · April 3, 2023 <p>p95HER2 invasive carcinoma. p95HER2 shown in magenta. Krt14 antibody staining shown in green.</p> ... Full text Cite

Supplementary Tables 1-5 for scRNAseq marker genes from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

Other · April 3, 2023 <p>Supplementary Table 1: Cluster-specific markers from all cells (8,486 cells) Supplementary Table 2: Cluster-specific markers from all epithelial cells (3,843 cells) Supplementary Table 3: Cluster-specific markers from all immune cells (1,8 ... Full text Cite

Movie 2 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

Other · April 3, 2023 <p>d16HER2 labelled sidebuds. d16HER2 shown in yellow. Krt14 antibody staining shown in green.</p> ... Full text Cite

Data from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase

Other · April 3, 2023 <div>Abstract<p>HER2-positive breast cancers are among the most heterogeneous breast cancer subtypes. The early amplification of HER2 and its known oncogenic isoforms provide a plausible mechanism in which distinct programs of tumor het ... Full text Cite